|
|
Article: Immunovaccine Inc. Signs Collaboration Agreement with National Cancer Institute.
- Article from:
- Marketwire Canada
- Article date:
- November 10, 2009
CopyrightCOPYRIGHT 2009 Canadian Corporate News. News Provided by Comtex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HALIFAX, NOVA SCOTIA, Nov 10, 2009 (Marketwire via COMTEX) -- Immunovaccine Inc. (TSX VENTURE:IMV), a vaccine development company, has signed a collaborative agreement with the National Cancer Institute (NCI) in Maryland, USA. The research collaboration involves formulating NCI's cancer vaccine antigens in DepoVax(TM), Immunovaccine's vaccine enhancement system.
"NCI is a world leader in the study of cancer biology and cancer therapy and we look forward to seeing how our enhanced DepoVax(TM) delivery system improves immune responses to treat cancer," said Dr. Marc Mansour, vice president of R&D at Immunovaccine.
The research team at Immunovaccine will ...